脏缩在HFpEF中的作用
Dawood Jamil1, Sanaullah Mojaddedi2,3, Patrick Kollman4
1Department of Internal Medicine, Henry Ford Hospital, Detroit, MI 48202, USA.
Journal of clinical medicine
|June 26, 2025
概括
脏缺血 (RDN) 显示出对心力衰竭与保留喷射分数 (HFpEF) 的承诺. 这种手术向同情神经,有可能改善心脏功能,并为这种复杂的疾病提供新的治疗途径.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 医疗器械 医疗器械
背景情况:
- 在全球范围内,心力衰竭与保存的喷射分数 (HFpEF) 影响了数以百万计的患者,造成了大量未满足的医疗需求.
- 对于HFpEF存在有限的有效药理治疗方法,这引发了对非药理干预的兴趣.
- 脏缩 (RDN),最初用于高血压,正在成为HFpEF的潜在治疗方法.
研究的目的:
- 审查HFpEF的病理生理学.
- 探索RDN对HFpEF心脏重塑和神经激素激活的影响.
- 讨论目前的临床证据和RDN对HFpEF的治疗潜力.
主要方法:
- 关于RDN影响的临床前动物研究的审查.
- 对最近的临床研究分析,研究HFpEF患者的RDN.
- 检查RDN在同情通路上的作用机制.
主要成果:
- 临床前数据表明,RDN可以改善心脏纤维化,减少炎症,控制高血压.
- 新兴的临床数据表明,RDN对高高压血压患者,特别是那些患有失控高血压患者的潜在益处.
- RDN准脏交感神经,以减少不适应的心脏重塑.
结论:
- RDN为HFpEF提供了一个有前途的治疗选择.
- 需要进一步的临床研究来确定RDN在HFpEF中的有效性和安全性.
- 了解神经和心脏功能之间的相互作用是优化RDN治疗的关键.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
524
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
524
Heart Failure Drugs: Diuretics
505
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
505
Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34
Heart Failure II: Pathophysiology
59
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
59
Heart Failure Drugs: β-Blockers
445
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
445
Pathophysiology of Heart Failure
1.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K


